Effect of Boceprevir Therapy on HCV-specific T Cell Responses: Perspectives of Immune Monitoring and Immune Therapy
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2013
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms Boce-Par
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2013 Planned end date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 12 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.